ClinicalTrials.gg
WithdrawnNCT07060183Updated Jul 11, 2025

Aortic Valve Replacement for Moderate Aortic Stenosis With Left Ventricular Decompensation Early Feasibility Study

An interventional study of Ross procedure in Moderate Aortic Valve Stenosis, sponsored by Dermed Diagnostics, Inc.. Withdrawn. Open to participants aged 55 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Dermed Diagnostics, Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Lack of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
55 Years to 79 Years
Sex
All
01

Study summary

Obtain safety and effectiveness data to support expansion for aortic valve replacement to include patients with moderate aortic stenosis and left ventricular decompensation.

Read the detailed description

Single-center prospective study. Subjects with moderate aortic stenosis and left ventricular decompensation will receive aortic valve replacement by the Ross procedure.

02

Conditions studied

  • Moderate Aortic Valve Stenosis

Keywords

  • aortic
  • stenosis
  • valve
  • decompensation
  • moderate
03

In context

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Lead sponsor

Dermed Diagnostics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate aortic stenosis, defined by transthoracic echocardiograph
  • Max aortic velocity less than 4.0 m/sec.
  • Mean aortic gradient less than 40.0 mmHg.
  • 1.0 cm2 \< Aortic Valve Area \< 1.5 cm2.
  • Left ventricular decompensation

Exclusion criteria

Exclusion Criteria:

  • Not suitable for the Ross procedure.
  • Documented history of cardiac amyloidosis.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Intervention

    Aortic Valve Replacement

    Procedure: Ross procedure

  • No intervention
    Control

    No intervention

Interventions

  • ProcedureRoss procedure

    aortic valve replacement

06

What researchers measure

Primary outcomes

  1. Composite rates of all-cause mortality or morbidity

    Composite rate of all-cause mortality, all-stroke, life threatening or fatal bleeding, acute kidney injury, hospitalization due to procedure-related complication, or valve dysfunction requiring reintervention.

    Time frame: 12 months

Secondary outcomes

  1. Left ventricular compensation

    Improvement in left ventricular function from baseline

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
Jul 11, 2025
StartEst.
Jan 2027
Primary completionEst.
Dec 2028
CompletionEst.
Feb 2029
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07060183
Lead sponsor
Dermed Diagnostics, Inc.
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Jan 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Jul 11, 2025

Study contacts

Arthur P DeMarzo
study director · Dermed Diagnostics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion